Table 2. The serum selenium level and selenium deficiency prevalence in clinicopathological groups of patients with papillary thyroid carcinoma.
| Variable | n (%) | Selenium (µg/l) | Selenium deficiency (<70) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean±SD | P-value | No (%) | Yes (%) | P-value | |||||
| Multifocality | |||||||||
| Absent | 160 (87.9) | 95.11±20.14 | 0.822 | 139 (86.9) | 21 (13.1) | 1.0 | |||
| Present | 22 (12.1) | 94.09±18.53 | 19 (86.4) | 3 (13.6) | |||||
| Extrathyroidal extension | |||||||||
| Absent | 175 (96.2) | 96.14±19.42 | <0.001 | 157 (89.7) | 18 (10.3) | <0.001 | |||
| Present | 7 (3.8) | 66.14±3.44 | 1 (14.3) | 6 (85.7) | |||||
| Capsular invasion | |||||||||
| Absent | 166 (91.2) | 95.67±19.66 | 0.138 | 147 (88.6) | 19 (11.4) | 0.042 | |||
| Present | 16 (8.8) | 87.94±21.71 | 11 (68.8) | 5 (31.3) | |||||
| Vascular Invasion | |||||||||
| Absent | 172 (94.5) | 95.49±19.74 | 0.161 | 152 (88.4) | 20 (11.6) | 0.029 | |||
| Present | 10 (5.5) | 86.40±21.85 | 6 (60.0) | 4 (40.0) | |||||
| Nodal involvement | |||||||||
| N0 | 154 (84.6) | 95.27±19.55 | 0.741 | 136 (88.3) | 18 (11.7) | 0.060 | |||
| N1a | 21 (11.5) | 94.86±20.61 | 18 (85.7) | 3 (14.3) | |||||
| N1b | 7 (3.8) | 89.29±27.45 | 4 (57.1) | 3 (42.9) | |||||
| Cancer stage | |||||||||
| I | 160 (87.9) | 99.31±17.16 | <0.001 | 158 (98.8) | 2 (1.3) | <0.001 | |||
| II | 11 (6.0) | 63.09±2.63 | 0 (0.0) | 11 (100) | |||||
| III | 4 (2.2) | 62.25±2.63 | 0 (0.0) | 4 (100) | |||||
| IVa | 6 (3.3) | 64.67±2.34 | 0 (0.0) | 6 (100) | |||||
| IVb | 1 (0.5) | 67.0±NA | 0 (0.0) | 1 (100) | |||||
| Histological type | |||||||||
| Classic | 154 (84.6) | 95.71±19.86 | 0.483 | 138 (89.6) | 16 (10.4) | 0.024 | |||
| Follicular | 24 (13.2) | 90.42±19.34 | 17 (70.8) | 7 (29.2) | |||||
| Tall cell | 4 (2.2) | 94.75±27.06 | 3 (75.0) | 1 (25.0) | |||||